December 20, 2019

Office of the Attorney General
State of Vermont

via email to AGO.highcostprescriptiondrugs@vermont.gov

Pursuant to 18 V.S.A.§4637(c), Biogen is hereby providing additional information related to the notice of the introduction of a new prescription drug in the commercial market as submitted on November 22, 2019:

NDC	Description	Commercial availability date	Wholesale Acquisition Cost*
64406-020-01	VUMERITY™ (diroximel fumarate) 231mg Starter Bottle (106 capsules)	11/22/2019	$6,388.62
64406-020-03	VUMERITY™ (diroximel fumarate) 231mg Maintenance Bottle (120 capsules)	11/22/2019	$7,232.88

*Price to wholesalers, without regard to prompt pay or other discounts, rebates, chargebacks, or any fees paid to wholesalers for services performed. Does not represent prices charged to other customers or classes of trade.

Additional information:

Requested Information	Biogen Submission
A description of the marketing and pricing plans used in the launch of the new drug in the United States and Internationally	Vumerity will be marketed to Healthcare Professionals, Patients, Payers and other appropriate audiences for use in patients with relapsing forms of Multiple Sclerosis. Biogen has a set of Pricing Principles that inform pricing decisions for its products. Those principles are: 1. Value to Patients 2. Present and Future Benefit to Society 3. Fulfilling our commitment to Innovation 4. Evolution toward Value Based Care 5. Affordability & Sustainability Further information on the Pricing Principles can be found at: https://www.biogen.com/content/dam/corporate/en_us/pdfs/BIOGEN_PricingPrinciplesInfographic_4-26-19.pdf
The estimated volume of patients who may be prescribed the drug	There are approximately 344,000 patients in the United States diagnosed with Relapsing forms of Multiple Sclerosis, the indicated usage for Vumerity. We are unable to estimate the number of patients who will be prescribed Vumerity.

Requested Information	Biogen Submission
Whether the drug was granted breakthrough therapy designation or priority review by the FDA prior to final approval	Vumerity was not granted breakthrough therapy designation or priority review.
The date and price of acquisition if the drug was not developed by the manufacturer	N/A

Please let me know if you need any additional information.

Best Regards,

T.J. Sheehan
Associate Director, Market Access Forecasting